Equities

Active Biotech AB publ

Active Biotech AB publ

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.387
  • Today's Change-0.010 / -2.40%
  • Shares traded380.07k
  • 1 Year change-48.97%
  • Beta0.3632
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments364253
Total Receivables, Net1.260.951.19
Total Inventory------
Prepaid expenses1.241.381.53
Other current assets, total------
Total current assets394456
Property, plant & equipment, net4.726.260.95
Goodwill, net------
Intangibles, net0.250.25--
Long term investments------
Note receivable - long term0.380.380.00
Other long term assets------
Total assets445157
LIABILITIES
Accounts payable3.173.532.76
Accrued expenses5.446.696.13
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.551.610.76
Other current liabilities, total0.230.240.26
Total current liabilities10129.90
Total long term debt3.004.430.23
Total debt4.556.040.99
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities131610
SHAREHOLDERS EQUITY
Common stock1.871.371.13
Additional paid-in capital3,4723,4313,386
Retained earnings (accumulated deficit)(3443)(3398)(3340)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity313547
Total liabilities & shareholders' equity445157
Total common shares outstanding362295253
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.